Discounted Cash Flow (DCF) Analysis Levered
CTI BioPharma Corp. (CTIC)
$5.44
+0.15 (+2.84%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | 25.15 | 26.29 | 3.34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -39.30 | -39.82 | -27.82 | -42.20 | -84.89 | -7.94 | -3.11 | -1.22 | -0.48 | -0.19 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -0.05 | -0.03 | -0.01 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -39.34 | -39.86 | -27.83 | -42.21 | -84.89 | -7.94 | -3.11 | -1.22 | -0.48 | -0.19 |
Weighted Average Cost Of Capital
Share price | $ 5.44 |
---|---|
Beta | 0.986 |
Diluted Shares Outstanding | 90.12 |
Cost of Debt | |
Tax Rate | 0.00 |
After-tax Cost of Debt | 5.10% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 7.396 |
Total Debt | 47.38 |
Total Equity | 490.24 |
Total Capital | 537.62 |
Debt Weighting | 8.81 |
Equity Weighting | 91.19 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | 25.15 | 26.29 | 3.34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -39.30 | -39.82 | -27.82 | -42.20 | -84.89 | -7.94 | -3.11 | -1.22 | -0.48 | -0.19 |
Capital Expenditure | -0.05 | -0.03 | -0.01 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
Free Cash Flow | -39.34 | -39.86 | -27.83 | -42.21 | -84.89 | -7.94 | -3.11 | -1.22 | -0.48 | -0.19 |
WACC | ||||||||||
PV LFCF | -84.89 | -7.41 | -2.70 | -0.99 | -0.36 | -0.13 | ||||
SUM PV LFCF | -11.59 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 7.19 |
Free cash flow (t + 1) | -0.19 |
Terminal Value | -3.66 |
Present Value of Terminal Value | -2.59 |
Intrinsic Value
Enterprise Value | -14.17 |
---|---|
Net Debt | -18.07 |
Equity Value | 3.89 |
Shares Outstanding | 90.12 |
Equity Value Per Share | 0.04 |